8-K: Aethlon Medical Secures $3.3M in Private Placement

Aethlon Medical, Inc. announced a private placement and warrant inducement deal, raising approximately $3.3 million in gross proceeds to fund operations and clinical trials.

Summary

• Aethlon Medical, Inc. entered into a securities purchase agreement with a single institutional investor for a private placement (PIPE Offering) on December 5, 2025.
• The PIPE Offering includes the issuance of 596,452 shares of common stock (or pre-funded warrants) and 1,043,791 common warrants to purchase common stock.
• The combined effective offering price for each share (or pre-funded warrant) and accompanying common warrant is $4.03.
• The common warrants will have an exercise price of $4.03 per share, exercisable upon shareholder approval, and will expire five and a half years from the shareholder approval date.
• The company also entered into a warrant inducement agreement with the same investor to exercise existing March 2025 and September 2025 Warrants.
• Under the inducement agreement, the exercise price of the existing warrants was reduced to $4.03 per share for cash exercises.
• The investor agreed to exercise 155,000 shares from March 2025 Warrants and 55,555 shares from September 2025 Warrants at the amended $4.03 exercise price.
• In consideration for the immediate exercise of existing warrants, the company will issue new unregistered warrants to purchase an aggregate of 368,471 shares of common stock.
• These new warrants will also have an exercise price of $4.03 per share, be exercisable upon shareholder approval, and expire five and a half years from the shareholder approval date.
• Gross proceeds from both the private placement and warrant inducement are estimated to be approximately $3.3 million, before deducting placement agent fees and other offering expenses.
• Maxim Group LLC acted as the sole placement agent, receiving a 6.5% cash fee on gross proceeds from both the PIPE and warrant inducement, up to $50,000 for expenses, and warrants to purchase 4.0% of the total shares and pre-funded warrants sold in the PIPE, exercisable at 125% of the per share purchase price ($5.0375).
• The company intends to use the net proceeds for working capital and general corporate purposes, including clinical trials.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the company successfully secured necessary capital for its operations and clinical trials. However, the dilution for existing shareholders and the reliance on future shareholder approval for warrant exercise temper the overall positive impact.

Positives

• Secured approximately $3.3 million in gross proceeds, providing capital for working capital and general corporate purposes, including clinical trials.
• The pricing of the offering at-the-market ($4.03 per share) under Nasdaq rules suggests a market-aligned valuation for the capital raise.
• The warrant inducement successfully encouraged the exercise of existing warrants, bringing in immediate cash.
• The company has agreed to file registration statements for the resale of all newly issued securities, providing liquidity pathways for investors.

Negatives

• The issuance of new shares and warrants will result in dilution for existing shareholders.
• The exercise of common warrants and new warrants is contingent on obtaining shareholder approval, which introduces a potential delay and uncertainty.
• Significant fees and expenses are associated with the capital raise, including a 6.5% cash fee to the placement agent on gross proceeds and additional warrants issued to the agent.
• Restrictions are placed on the company's ability to issue additional common stock or equivalents for certain periods following the closing, limiting future financing flexibility.

Risks

• The company's ability to raise additional capital in the future.
• The company's ability to maintain its Nasdaq listing.
• The successful completion of the development of the Hemopurifier.
• The company's ability to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases and in the transplant setting.
• The ability of the Hemopurifier to continue to show removal of platelet-derived EVs at a timepoint equivalent to a 4-hour HP treatment.
• The company's ability to achieve and realize the anticipated benefits from its potential milestones.
• The company's ability to submit applications to and obtain approval from additional Ethics Committees in Australia and India, including on the timing expected.
• The company's ability to initiate and continue its planned oncology clinical trials in Australia and India, including on the timing expected.
• The company's ability to manage and successfully complete its clinical trials, if initiated.
• The company's ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials.
• Potential dilution of outstanding shares of common stock due to the issuance of new securities.
• Market price of the company's publicly-traded securities may be negatively impacted by past or future open market or other transactions by purchasers, including short sales or derivative transactions.
• The company may incur liquidated damages if it fails to timely file or achieve effectiveness for the resale registration statements for the new warrants.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including funding clinical trials for its Hemopurifier product. The Hemopurifier is being advanced to address unmet needs in oncology and infectious diseases, with plans to initiate and continue planned oncology clinical trials in Australia and India. The company aims to demonstrate the utility of the Hemopurifier in cancer, infectious diseases, and transplant settings, and to achieve anticipated benefits from potential milestones.

Management Comments

• The company's current expectations and assumptions involve risks and uncertainties, and actual results may differ materially from forward-looking statements.
• Factors that may contribute to differences include the ability to raise additional capital, maintain Nasdaq listing, successfully develop the Hemopurifier, demonstrate its utility in various diseases, achieve milestones, obtain regulatory approvals in Australia and India, initiate and continue clinical trials, manage clinical trials, and manufacture the Hemopurifier in sufficient quantities.

Industry Context

Aethlon Medical, Inc. operates as a clinical-stage medical device company focused on developing products for oncology and infectious diseases. This financing event provides crucial capital for a company in this stage, where significant investment is required for research, development, and clinical trials. The successful completion of this private placement and warrant inducement allows Aethlon to continue advancing its Hemopurifier platform, aligning with the capital-intensive nature of the medical therapeutic industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience dilution from the issuance of new shares and warrants. However, the capital raise provides funding for ongoing operations and clinical trials, which could support long-term value creation.
• Investors (Purchaser/Holder): Will acquire new securities and benefit from a reduced exercise price on existing warrants, providing potential upside. They also receive registration rights for liquidity.
• Company: Receives approximately $3.3 million in gross proceeds, bolstering working capital and funding critical clinical development programs for the Hemopurifier.
• Placement Agent (Maxim Group LLC): Earns significant fees and warrants for facilitating the transaction.

Next Steps

• Closing of the PIPE Offering and Warrant Inducement, expected on or about December 8, 2025.
• Company to file a press release and Form 8-K disclosing the material terms of the transactions by the Disclosure Time.
• Company to file a registration statement to register the resale of the shares and warrant shares from the PIPE Offering no later than 30 calendar days following December 5, 2025.
• Company to file a resale registration statement for the new warrants issued under the inducement agreement on or before the 90th calendar day following December 5, 2025.
• Company to hold a special meeting of stockholders (or annual meeting) by January 8, 2026, to obtain Shareholder Approval for the issuance of shares underlying the common and new warrants.
• If Shareholder Approval is not obtained at the first meeting, the company will seek approval at the following two annual meetings.
• Company to use net proceeds for working capital and general corporate purposes, including advancing the Hemopurifier and initiating planned oncology clinical trials in Australia and India.

Key Dates

Recommendation

The capital raise provides essential funding for Aethlon Medical, a clinical-stage company, to continue its development programs. While the 'at-the-market' pricing and the securing of capital are positive, the associated dilution for existing shareholders and the contingency of shareholder approval for warrant exercise are notable. For a seasoned investor, this event is a necessary step in the company's lifecycle, but it doesn't fundamentally alter the long-term investment thesis in a way that would warrant a strong buy or sell recommendation based solely on this filing. The success of the underlying Hemopurifier technology and clinical trials remains the primary driver for future value.

Keywords

Aethlon Medical, AEMD, Private Placement, PIPE Offering, Warrant Inducement, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, SEC Filing, Nasdaq, Medical Therapeutic, Hemopurifier, Clinical Stage, Oncology, Infectious Disease